The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.

Read More

You might also be interested in reading Circle debuts Arc blockchain which Jeremy Allaire calls ‘more consequential’ than USDC.